Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Dawn of a new beginning

Dawn of a new beginning Allmendinger AAPS Open (2021) 7:1 AAPS Open https://doi.org/10.1186/s41120-021-00035-0 EDITORIAL Open Access 1,2 Andrea Allmendinger Welcome Pharmaceutical Scientist community! This is important the desire for open publishing, basically the my first editorial and I would like to take the opportun- concept of freely available research without restrictions on ity to sincerely thank AAPS and Springer Nature for use, has been increasing over the recent decade and this their trust, recognition, and support in stepping into this trend is continuing. In numerous cases, open access pub- leadership role — a responsible and challenging task! I lishing is also requested by funding bodies for example am excited to connect to the scientific community creat- those being part of cOAlition S, with the goal of making ing an open access space for pharmaceutical sciences. scientific content accessible to the global scientific com- I would like to welcome you, the readers, authors, and munity addressing the imbalance in access to information. reviewers of AAPS Open, and invite you to join me on a Especially during the current COVID-pandemic, this con- journey that we have started a couple of months ago. cept has been exemplified and publishers have made re- Initially launched in 2015, the journal underwent a lated scientific content fully accessible. transformative process during the last months/year to Last but not least, I would like to thank the previous edi- focus on its strength. We are excited to announce that torial board members and editors of the journal for their we went live again in April and I would like to thank time and energy that they have dedicated to the journal! you for your patience during this process! Likewise, I would like to welcome the new editorial advis- We have refined the scope of the journal and I would ory board and new team of editors, who form a strong like to highlight that besides original research articles, and diverse fundament on which to build the success of AAPS Open will accept a diverse range of secondary re- this journal. Stay tuned to hear more from the board, for search including white papers, commentaries, and per- example about special issue that we will initiate! spectives from experts in their field, as well as meeting With progressing vaccination coverage across the reports, and reviews or brief review articles. I expect a world in fighting the present COVID pandemic, I do feel diverse range of manuscript and opinion pieces from the dawn of a new beginning all around — in my profes- both academia and industry covering the breadth of sional environment, in my private environment, and pharmaceutical sciences. Personally, I am excited about when looking at diverse communication channels. Let’s the currently transforming scientific landscape, and I transfer this spirit to the journal and I am looking for- would like to specifically highlight new biopharmaceut- ward to receiving exciting manuscripts that we make ical modalities including cell, gene, and nucleotide-based publically available to the scientific community advan- therapeutics bringing hope to thousands of patients cing pharmaceutical sciences! around the globe. Thus, I would like to encourage sub- Author’s contributions missions of opinion pieces to educate the pharmaceut- The author read and approved the final manuscript. ical community and advancing community knowledge Declarations about these new treatment modalities. I would like to highlight that AAPS Open is a fully open Competing interests access, fully peer-reviewed journal, and the flagship of The authors declare that they have no competing interests. open access publishing of the American Association of Pharmaceutical Scientists. The acceptance but more Publisher’sNote Correspondence: andrea.allmendinger@pharmazie.uni-freiburg.de Springer Nature remains neutral with regard to jurisdictional claims in Pharmaceutical Development Biologics Europe, F. Hoffmann-La Roche, 4007 published maps and institutional affiliations. Basel, Switzerland Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmaceutical Sciences, University of Freiburg, 79104 Freiburg, Germany © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AAPS Open Springer Journals

Dawn of a new beginning

AAPS Open , Volume 7 (1) – Jun 11, 2021

Loading next page...
 
/lp/springer-journals/dawn-of-a-new-beginning-Dm9FaXmyes
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2021
eISSN
2364-9534
DOI
10.1186/s41120-021-00035-0
Publisher site
See Article on Publisher Site

Abstract

Allmendinger AAPS Open (2021) 7:1 AAPS Open https://doi.org/10.1186/s41120-021-00035-0 EDITORIAL Open Access 1,2 Andrea Allmendinger Welcome Pharmaceutical Scientist community! This is important the desire for open publishing, basically the my first editorial and I would like to take the opportun- concept of freely available research without restrictions on ity to sincerely thank AAPS and Springer Nature for use, has been increasing over the recent decade and this their trust, recognition, and support in stepping into this trend is continuing. In numerous cases, open access pub- leadership role — a responsible and challenging task! I lishing is also requested by funding bodies for example am excited to connect to the scientific community creat- those being part of cOAlition S, with the goal of making ing an open access space for pharmaceutical sciences. scientific content accessible to the global scientific com- I would like to welcome you, the readers, authors, and munity addressing the imbalance in access to information. reviewers of AAPS Open, and invite you to join me on a Especially during the current COVID-pandemic, this con- journey that we have started a couple of months ago. cept has been exemplified and publishers have made re- Initially launched in 2015, the journal underwent a lated scientific content fully accessible. transformative process during the last months/year to Last but not least, I would like to thank the previous edi- focus on its strength. We are excited to announce that torial board members and editors of the journal for their we went live again in April and I would like to thank time and energy that they have dedicated to the journal! you for your patience during this process! Likewise, I would like to welcome the new editorial advis- We have refined the scope of the journal and I would ory board and new team of editors, who form a strong like to highlight that besides original research articles, and diverse fundament on which to build the success of AAPS Open will accept a diverse range of secondary re- this journal. Stay tuned to hear more from the board, for search including white papers, commentaries, and per- example about special issue that we will initiate! spectives from experts in their field, as well as meeting With progressing vaccination coverage across the reports, and reviews or brief review articles. I expect a world in fighting the present COVID pandemic, I do feel diverse range of manuscript and opinion pieces from the dawn of a new beginning all around — in my profes- both academia and industry covering the breadth of sional environment, in my private environment, and pharmaceutical sciences. Personally, I am excited about when looking at diverse communication channels. Let’s the currently transforming scientific landscape, and I transfer this spirit to the journal and I am looking for- would like to specifically highlight new biopharmaceut- ward to receiving exciting manuscripts that we make ical modalities including cell, gene, and nucleotide-based publically available to the scientific community advan- therapeutics bringing hope to thousands of patients cing pharmaceutical sciences! around the globe. Thus, I would like to encourage sub- Author’s contributions missions of opinion pieces to educate the pharmaceut- The author read and approved the final manuscript. ical community and advancing community knowledge Declarations about these new treatment modalities. I would like to highlight that AAPS Open is a fully open Competing interests access, fully peer-reviewed journal, and the flagship of The authors declare that they have no competing interests. open access publishing of the American Association of Pharmaceutical Scientists. The acceptance but more Publisher’sNote Correspondence: andrea.allmendinger@pharmazie.uni-freiburg.de Springer Nature remains neutral with regard to jurisdictional claims in Pharmaceutical Development Biologics Europe, F. Hoffmann-La Roche, 4007 published maps and institutional affiliations. Basel, Switzerland Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmaceutical Sciences, University of Freiburg, 79104 Freiburg, Germany © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Journal

AAPS OpenSpringer Journals

Published: Jun 11, 2021

There are no references for this article.